Tyrosine administration decreases vulnerability to ventricular fibrillation in the normal canine heart.
Intravenous infusion of tyrosine (1, 2, or 4 milligrams per kilogram) for 20 to 30 minutes caused dose-dependent increases in the ventricular fibrillation threshold in normal dogs. Administration of valine, a neutral amino acid that competes with tyrosine for uptake at the blood-brain barrier, in a dose equimolar to the most effective dose of tyrosine, slightly decreased the ventricular fibrillation threshold when given alone and significantly blocked elevation of the ventricular fibrillation threshold after tyrosine infusion. Hence, tyrosine, presumably acting in the central nervous system, can protect against certain ventricular arrhythmias.
D000818:Animals; D001812:Blood-Brain Barrier; D002395:Catecholamines / Q000378:metabolism; D004195:Disease Models, Animal; D004285:Dogs; D014443:Tyrosine / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000627:therapeutic use*; D014633:Valine / Q000494:pharmacology; D014693:Ventricular Fibrillation / Q000517:prevention & control*
D002395:Catecholamines; D014443:Tyrosine; D014633:Valine